Overview
Osimertinib is a third-generation, oral EGFR tyrosine kinase inhibitor designed to target specific EGFR mutations, particularly exon 19 deletions and exon 21 L858R mutations. It plays an important role in the targeted management of eligible patients with EGFR-mutated non-small cell lung cancer (NSCLC).